Adverum Biotechnologies, Inc.

NasdaqCM:ADVM Voorraadrapport

Marktkapitalisatie: US$154.1m

Adverum Biotechnologies Toekomstige groei

Future criteriumcontroles 2/6

Adverum Biotechnologies's earnings are forecast to decline at 14.7% per annum while its annual revenue is expected to grow at 50% per year. EPS is expected to grow by 10.4% per annum.

Belangrijke informatie

-14.7%

Groei van de winst

10.4%

Groei van de winst per aandeel

Biotechs winstgroei27.1%
Inkomstengroei50.0%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Good

Laatst bijgewerkt16 Oct 2024

Recente toekomstige groei-updates

Recent updates

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Feb 24
We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Sep 07
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Aug 11

Adverum gains 13% to reach three-month high after Truist upgrade

Jul 07

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

May 12
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Jul 17
We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Adverum Biotechnologies: An Uncertain Path Forward

May 05

Adverum Bio presents long-term data from ADVM-022 trial in wet AMD

May 03

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Apr 06
We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

Feb 13
Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy

Feb 02

Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares

Jan 22
Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares

Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market

Jan 11

Adverum Biotechnologies announces new GMP gene therapy manufacturing facility

Jan 07

How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?

Dec 31
How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?

Winst- en omzetgroeiprognoses

NasdaqCM:ADVM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202612-159-170N/A5
12/31/20258-134-74-1148
12/31/20240-102-96-888
6/30/2024N/A-100-89-88N/A
3/31/2024N/A-113-93-92N/A
12/31/20234-117-92-91N/A
9/30/20234-126-89-88N/A
6/30/20234-133-97-96N/A
3/31/20234-146-109-102N/A
12/31/2022N/A-155-120-108N/A
9/30/2022N/A-156-131-115N/A
6/30/2022N/A-154-130-109N/A
3/31/2022N/A-155-133-114N/A
12/31/20218-146-123-108N/A
9/30/20218-149-116-104N/A
6/30/20218-138-115-105N/A
3/31/20218-123-97-88N/A
12/31/2020N/A-118-91-79N/A
9/30/2020N/A-99-91-72N/A
6/30/20200-87-77-55N/A
3/31/20200-73-71-50N/A
12/31/20190-64-68-49N/A
9/30/20190-61-58-47N/A
6/30/20191-66-60-54N/A
3/31/20191-70-57-54N/A
12/31/20182-73-55-54N/A
9/30/20182-72-54-53N/A
6/30/20182-65-47-47N/A
3/31/20182-57N/A-47N/A
12/31/20172-56N/A-45N/A
9/30/20172-64N/A-42N/A
6/30/20172-64N/A-41N/A
3/31/20172-114N/A-38N/A
12/31/20161-114N/A-38N/A
9/30/20162-105N/A-39N/A
6/30/20162-105N/A-39N/A
3/31/20162-53N/A-40N/A
12/31/20152-47N/A-35N/A
9/30/20152-44N/A-31N/A
6/30/20151-38N/A-27N/A
3/31/20151-36N/A-12N/A
12/31/20141-29N/A-6N/A
9/30/20140-22N/A-1N/A
6/30/20140-14N/A3N/A
3/31/20140-7N/A-3N/A
12/31/20130-5N/A-2N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: ADVM is forecast to remain unprofitable over the next 3 years.

Winst versus markt: ADVM is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: ADVM is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: ADVM's revenue (50% per year) is forecast to grow faster than the US market (8.9% per year).

Hoge groei-inkomsten: ADVM's revenue (50% per year) is forecast to grow faster than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if ADVM's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven